Halozyme Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Halozyme Therapeutics

05/08/2025 22:01

Halozyme Therapeutics Inc HALO.OQ reported quarterly adjusted earnings of $1.54​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 91 cents.  The mean expectation of nine analysts for the quarter was for earnings of $1.27 per share. Wall Street expected results to range from $1.20  to $1.41 per share.

Revenue rose 40.8% to $325.72 million from a year ago; analysts expected $285.92 million.

Halozyme Therapeutics Inc's reported EPS for the quarter was $1.33​.

The company reported quarterly net income of $165.16 million.

Halozyme Therapeutics Inc shares had risen by 15.3% this quarter and gained 25.5% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 3.3% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy," 4 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is  "buy."

Wall Street's median 12-month price target for Halozyme Therapeutics Inc is $68.50, about 12.4% above its last closing price of $59.99

This summary was machine generated from LSEG data August 5 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
1.27
1.54
Beat
Mar. 31 2025
0.95
1.11
Beat
Dec. 31 2024
1.16
1.26
Beat
Sep. 30 2024
0.98
1.27
Beat